FY2026 EPS Estimates for Humacyte Increased by HC Wainwright

Humacyte, Inc. (NASDAQ:HUMA – Free Report) – Stock analysts at HC Wainwright raised their FY2026 earnings per share estimates for shares of Humacyte in a research report issued on Wednesday, November 11th. HC Wainwright analyst S. Ramakanth now forecasts that the company will earn ($0.39) per share for the year, up from their prior estimate of ($0.46). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Humacyte’s current full-year earnings is ($0.38) per share. HC Wainwright also issued estimates for Humacyte’s Q4 2026 earnings at ($0.10) EPS, Q1 2027 earnings at ($0.08) EPS, Q3 2027 earnings at ($0.07) EPS, Q4 2027 earnings at ($0.07) EPS, FY2027 earnings at ($0.31) EPS and FY2028 earnings at ($0.11) EPS.

Humacyte (NASDAQ:HUMA – Get Free Report) last issued its earnings results on Wednesday, August 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.05). Humacyte had a negative return on equity of 612.88% and a negative net margin of 3,955.05%. The company had revenue of $0.41 million during the quarter, compared to analyst estimates of $1.04 million.

Several other research analysts have also recently commented on HUMA. BTIG Research reiterated a “buy” rating and issued a $2.00 target price on shares of Humacyte in a report on Tuesday, November 10th. Barclays boosted their price target on shares of Humacyte from $0.50 to $0.60 and gave the company an “equal weight” rating in a report on Wednesday. Cantor Fitzgerald set a $1.00 price target on shares of Humacyte in a research report on Thursday. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Humacyte in a research note on Friday, October 2nd. Finally, Wall Street Zen raised shares of Humacyte to a “sell” rating in a research note on Saturday. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Humacyte currently has a consensus rating of “Moderate Buy” and a consensus target price of $4.48.

Get Our Latest Report on Humacyte

Humacyte Trading Down 6.2%

NASDAQ HUMA traded down $0.04 on Friday, hitting $0.56. 4,625,603 shares of the company were exchanged, compared to its average volume of 4,968,351. The company’s 50 day moving average price is $0.49 and its 200-day moving average price is $0.78. The company has a debt-to-equity ratio of 3.65, a current ratio of 3.34 and a quick ratio of 5.74. The firm has a market capitalization of $155.12 million, a P/E ratio of -1.27 and a beta of 2.64. Humacyte has a twelve month low of $0.34 and a twelve month high of $1.52.

Hedge Funds Weigh In On Humacyte

A number of hedge funds have recently modified their holdings of the stock. Marshall Wace LLP increased its holdings in shares of Humacyte by 1,548.0% during the 3rd quarter. Marshall Wace LLP now owns 2,996,553 shares of the company’s stock valued at $1,558,000 after acquiring an additional 2,814,722 shares during the last quarter. Empowered Funds LLC bought a new position in shares of Humacyte in the 3rd quarter valued at approximately $81,000. State Street Corp lifted its holdings in Humacyte by 6.9% in the 3rd quarter. State Street Corp now owns 900,646 shares of the company’s stock worth $466,000 after purchasing an additional 58,109 shares during the last quarter. Private Advisor Group LLC acquired a new stake in Humacyte in the 3rd quarter worth approximately $491,000. Finally, HBK Investments L P acquired a new stake in Humacyte in the 2nd quarter worth approximately $617,000. 44.71% of the stock is owned by institutional investors and hedge funds.

Humacyte News Summary

These are some of the HUMA news items that stood out recently:

  • Positive Sentiment: HC Wainwright raised its estimated loss per share for FY2026 to $0.39 from $0.46, and narrowed its projected losses for Q4 2026 and Q1 2027. The firm maintained its Buy rating.
  • Positive Sentiment: StoneX reiterated its Speculative Buy rating, while a separate roundup highlighted Humacyte among healthcare stocks with bullish analyst views. StoneX Reiterates Speculative Buy Rating on Humacyte Analysts Are Bullish on These Healthcare Stocks
  • Negative Sentiment: HC Wainwright trimmed estimates for FY2027 and FY2028, and lowered projected Q3 and Q4 2027 results. It now expects a $0.31-per-share loss in FY2027 and a $0.11 loss in FY2028, signaling a slower path to profitability than previously forecast.

About Humacyte

(Get Free Report)

Humacyte, Inc. is a biotechnology company developing bioengineered human tissues for vascular repair and other medical applications. Its technology uses human vascular cells to create vessels that are processed to remove the cells, leaving an acellular structure designed for implantation. The company’s lead product, Symvess, is an acellular tissue-engineered vessel for treating extremity arterial injuries in adults when a patient’s own vein cannot be used for surgical revascularization. The U.S. Food and Drug Administration approved Symvess in December 2024.

Featured Stories

Earnings History and Estimates for Humacyte (NASDAQ:HUMA)

Receive News & Ratings for Humacyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humacyte and related companies with MarketBeat.com's FREE daily email newsletter.